PRP for Glenohumeral Osteoarthritis

Description

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

Conditions

Shoulder Osteoarthritis

Talk to us

Study Overview

On this page

Study Details

Study overview

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

Outcomes Following Single Injections of Low-dose Platelet-rich Plasma (PRP), High-dose PRP, or Saline in Patients With Glenohumeral OA: a Randomized Controlled Trial

PRP for Glenohumeral Osteoarthritis

Condition
Shoulder Osteoarthritis
Intervention / Treatment

-

Contacts and Locations

New York

Hospital for Special Surgery, New York, New York, United States, 10021

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18-100 years old
  • * Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss
  • * At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy
  • * MRI of the affected joint
  • * Transient relief of symptoms after a diagnostic intra-articular injection into the joint
  • * Email address or network access
  • * Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection
  • * Prior platelet-rich plasma injection
  • * Steroid injection within 3 months of the initial injection
  • * Hyaluronic acid within 6 months of the initial injection
  • * Involved in workers' compensation or active litigation involving the affected joint
  • * History of Plavix use
  • * Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune/autoinflammatory disease)
  • * Presence of acute fractures or gross mechanical deformities
  • * Concurrent "uncontrolled" cervical disorders

Ages Eligible for Study

18 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Hospital for Special Surgery, New York,

Study Record Dates

2025-09-01